Imunon Inc (IMNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Imunon Inc (IMNN) has a cash flow conversion efficiency ratio of -1.186x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.99 Million) by net assets ($3.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Imunon Inc (IMNN) net asset quality to measure how much of total assets are equity-financed.
Imunon Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Imunon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Imunon Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Imunon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Imunon Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ARIP Public Company Limited
BK:ARIP
|
0.160x |
|
Petro-Victory Energy Corp
V:VRY
|
0.095x |
|
Bon Natural Life Ltd
NASDAQ:BON
|
0.076x |
|
IP Group
LSE:IPO
|
0.000x |
|
International Personal Finance PLC
LSE:IPF
|
-0.018x |
|
Avenir Telecom S.A
PA:AVT
|
-3.784x |
|
Lifecare AS
OL:LIFE
|
3.325x |
|
Delta Manufacturing Limited
NSE:DELTAMAGNT
|
-0.091x |
Annual Cash Flow Conversion Efficiency for Imunon Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Imunon Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Imunon Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.06 Million | $-13.90 Million | -1.968x | +55.70% |
| 2024-12-31 | $4.24 Million | $-18.85 Million | -4.442x | -212.65% |
| 2023-12-31 | $13.39 Million | $-19.02 Million | -1.421x | -80.42% |
| 2022-12-31 | $29.33 Million | $-23.10 Million | -0.788x | -170.85% |
| 2021-12-31 | $55.80 Million | $-16.22 Million | -0.291x | +65.35% |
| 2020-12-31 | $18.61 Million | $-15.62 Million | -0.839x | +39.69% |
| 2019-12-31 | $14.56 Million | $-20.26 Million | -1.392x | -312.24% |
| 2018-12-31 | $20.86 Million | $-7.04 Million | -0.338x | +45.84% |
| 2017-12-31 | $26.70 Million | $-16.64 Million | -0.623x | +77.19% |
| 2016-12-31 | $6.73 Million | $-18.38 Million | -2.733x | -167.43% |
| 2015-12-31 | $20.39 Million | $-20.83 Million | -1.022x | -57.08% |
| 2014-12-31 | $32.83 Million | $-21.35 Million | -0.651x | -115.28% |
| 2013-12-31 | $31.52 Million | $-9.53 Million | -0.302x | +83.68% |
| 2012-12-31 | $11.96 Million | $-22.14 Million | -1.851x | -113.22% |
| 2011-12-31 | $26.19 Million | $-22.74 Million | -0.868x | -129.72% |
| 2010-12-31 | $-4.58 Million | $-13.37 Million | 2.921x | +3251.52% |
| 2009-12-31 | $10.04 Million | $-930.33K | -0.093x | -180.16% |
| 2008-12-31 | $19.73 Million | $2.28 Million | 0.116x | +136.99% |
| 2007-12-31 | $30.65 Million | $-9.58 Million | -0.313x | -113.84% |
| 2006-12-31 | $-3.20 Million | $-7.23 Million | 2.260x | +195.98% |
| 2005-12-31 | $3.43 Million | $-8.06 Million | -2.354x | -102.16% |
| 2004-12-31 | $11.97 Million | $-13.94 Million | -1.165x | -72.38% |
| 2003-12-31 | $13.45 Million | $-9.09 Million | -0.676x | +88.76% |
| 2002-12-31 | $1.52 Million | $-9.11 Million | -6.008x | -157.70% |
| 2001-12-31 | $2.67 Million | $-6.22 Million | -2.332x | -426.22% |
| 2000-12-31 | $8.73 Million | $-3.87 Million | -0.443x | +80.74% |
| 1999-12-31 | $1.00 Million | $-2.30 Million | -2.300x | -301.53% |
| 1998-12-31 | $-1.85 Million | $-2.11 Million | 1.141x | +143.19% |
| 1997-12-31 | $-2.46 Million | $-1.15 Million | 0.469x | +316.77% |
| 1996-12-31 | $6.76 Million | $-1.46 Million | -0.216x | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more